Supernus Pharmaceuticals (SUPN) is Benefiting from Its Strength in Financial Position

Core Insights - Third Avenue Small-Cap Value Fund reported a return of 7.18% in Q3 2025, underperforming the MSCI USA Small-Cap Value Index at 8.97% and the Russell 2000 Value Index at 12.60% [1] - The fund's performance was positively influenced by a diverse range of businesses, with Supernus Pharmaceuticals, Inc. being the largest contributor [3] Company Performance - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) experienced a one-month return of -4.85% but saw a significant 29.42% increase in value over the past 52 weeks, closing at $47.11 per share with a market capitalization of $2.691 billion on November 5, 2025 [2] - The company is benefiting from a strong financial position, current profitability, an expanding neurology drug portfolio, and effective capital allocation, which facilitated a successful acquisition during the quarter [3] Hedge Fund Interest - Supernus Pharmaceuticals, Inc. was held by 25 hedge fund portfolios at the end of Q2 2025, a slight decrease from 26 in the previous quarter, indicating a stable but cautious interest among hedge funds [4]